<table>
<thead>
<tr>
<th>TITe:</th>
<th>Nursing Guidelines for the Management of Children with Methylmalonic Aciduria</th>
<th>REVISION NO:</th>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>LEAD AUTHOR:</td>
<td>Eilish O’Connell</td>
<td>EFFECTIVE FROM:</td>
<td>07/07/2016</td>
</tr>
<tr>
<td>APPROVED BY:</td>
<td>Dr Ahmad Monavari</td>
<td>REVIEW DATE:</td>
<td>07/07/2018</td>
</tr>
<tr>
<td>NO. OF PAGES:</td>
<td>Page 1 of 17</td>
<td>SUPERCEDES:</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**TITLE: NURSING GUIDELINES FOR THE MANAGEMENT OF CHILDREN WITH METHYLMALONIC ACIDURIA**

**NAME/TITLE:** Eilish O’Connell, Clinical Education Facilitator, NCIMD

**SIGNATURE:**

**DATE:**

**NAME/TITLE:** Catherine McDonnell, Clinical Nurse Manager, NCIMD

**SIGNATURE:**

**DATE:**

**NAME/TITLE:** Dr Ahmad Monavari, Director of NCIMD (National Centre for Inherited Metabolic Disorders)

**SIGNATURE:**

**DATE:**
CONTENTS

1. PURPOSE: .................................................................3

2. DEFINITIONS: ..........................................................3

3. PRESENTATION: ..........................................................4

4. DIAGNOSIS: .................................................................4

5. MANAGEMENT: ............................................................5

6. NURSING MANAGEMENT OF THE PATIENT WITH METHYLMALONIC ACIDURIA .........7

7. REVIEW: ...........................................................................17

8. REFERENCES: ...............................................................17
1. PURPOSE:
The objectives in preparation of Nursing Guidelines for Management of Inherited Metabolic Disorders (IMD) are to increase the knowledge base of nursing staff involved in the delivery of care to patients with an IMD, provide a resource material for reference and ultimately ensure the consistent delivery of high quality care to patients attending the National Centre for Metabolic Disorders (NCIMD).

Readers of this document are reminded that prescription of dietary regimes and all medications (including insulin, minerals, vitamins and trace elements) is the responsibility of the Metabolic Consultant. These guidelines may only be used under the supervision and guidance of a Metabolic Consultant.

The document authors wish to thank the various Doctors, Nurses, parents and patients who have worked in and attended the National Centre throughout the years, contributing greatly in the process to our knowledge and experience of Inherited Metabolic Disorders.

2. DEFINITIONS:
Methylmalonic Aciduria (M.M.A) is a recessively inherited disorder which is caused by a deficiency of methylmalonyl-CoA mutase (Ogier de Baulny et al, 2012). The enzyme is a vitamin B12 dependant enzyme. Patients with M.M.A are unable to metabolise the amino acids isoleucine, methionine, threonine, valine and some fats (Yannicelli, 1988)

This condition is caused by:
- Decreased or absent enzyme (methylmalonyl CoA mutase) activity.
- Inadequate amounts of adenosylcobalamin (Vit. B12) due to dietary limitations, poor intake or inherited defects of Vit. B12 metabolism.

With MMA the offending organic acid metabolites of Propionic acid and Methylmalonic acid accumulate in body fluids. These substances then spill into the urine. The excessive build-up of these substances causes a secondary deficiency of Co-enzyme A (CoA) causing the symptoms of Methylmalonic Aciduria.

PREVALENCE 1: 50,000  (Ogier de Baulny et al, 2012)
3. PRESENTATION:

Symptoms of M.M.A. may occur in the first days of life, intermittently later in infancy, or chronically, as the child grows. Acute infection or excessive protein intake may trigger symptoms such as

- Refusal to eat
- Poor sucking reflex
- Vomiting
- Dehydration is a frequent finding in patients with MMA (Ogier de Baulny et al, 2012).
- Acidosis
- Failure to thrive
- Lethargy
- Seizures
- Developmental delay

Where left untreated, M.M.A. may result in developmental delay and/or death.

4. DIAGNOSIS:

4.1. Diagnosis is suspected on the clinical presenting signs & symptoms of the patient and on examination of laboratory investigation results i.e.

- Metabolic acidosis
- Hypoglycaemia
- Hyperlactataemia
- Hyperglycinaemia
- Hepatomegaly
- Hyperammonaemia
- Raised lactate, pyruvate
- Neutropenia (bone marrow depression is caused by Propionic acid metabolites).
- Thrombocytopenia
- Elevated urea and creatinine

4.2. Diagnosis is confirmed on the following;

- Clinical presentation
- Acylcarnitines (increased propionylcarnitine)
- Analysis of urine organic acids - (Highly suggestive diagnostic metabolites are methylmalonic acid & methyl citrate). The organic acids are nearly always abnormal during times of stress/illness and can be otherwise commonly normal between acute illnesses (Van Gosen, 2008)
- Serum amino acids. Glycine and Alaninine accumulates in plasma (Harris, 1988; Ogier de Baulny et al, 2012).
- Skin biopsy – to detect decreased amounts of enzyme activity.
**Mutational analysis**
Further tests will determine if the problem is due to deficiency of the enzyme or deficiency of adenosylcobalamin vitamin B$_{12}$

### 4.3. Newborn Screening / High Risk Screening
Methylmalonic Aciduria is currently not screened for in the Irish Newborn Population. High Risk Screening will be performed in the Maternity Hospital on siblings born to families with a known positive history (in consultation with the Metabolic Consultant). Prenatal diagnosis is possible by chorionic villus sampling in the first trimester or direct measurement of metabolites in amniotic fluid in 2$^{nd}$ trimester (Ogier de Baulny et al, 2012).

### 5. MANAGEMENT:

#### Emergency Treatment

**5.1. Protein Restriction;**
- Stop natural protein intake (infant formula / breast feeding / food products which are sources of protein).
- Rehydration - MMA is very well cleared by urinary excretion, hydration is thus the mainstay of treatment.
- Ensure adequate calorie intake to prevent catabolism and promote anabolism.
- Administration of intravenous glucose, lipids and for more severe presentations, condition specific IV amino acid mixture - to minimize ammonia production from endogenous protein breakdown.
- Haemodialysis or Peritoneal dialysis may be recommended on initial presentation with markedly elevated propionic acid metabolites and elevated ammonia levels.
- Administration of Carnitine – this is essential for the transport of fats across the mitochondria, but is lost in urine bound to organic acids when amino acidopathies occur.

**5.2. After initial treatment for acidosis, long-term treatment consists of:**
- Restrict intake of isoleucine, threonine, methionine and valine (natural protein) and odd-chain fatty acids.
- Supplement natural protein intake with a synthetic amino acid drink, which is free from the offending amino acids.
- Ensure adequate calorie intake to prevent catabolism
- ‘Free foods’ (i.e. non-protein) e.g. fruit, vegetables, sugars, fats and specially manufactured low-protein foods.
- Administration of vitamin and mineral supplements.
• If tests show adenosylcobalamin (Vit. B12) aides M.C.M. activity, it may be given intramuscularly, either daily or on alternate days (as per doctor’s prescription). Neonatal forms are rarely vitamin responsive (Ogier de Baulny et al, 2012)
• Large doses of carnitine are given orally or intravenously to assist the excretion of organic metabolites. It transports fatty acid into the mitochondria where they can be utilised for energy.
• Metronidazole (antibiotic) is used to clear the gut bacteria, which is responsible for 40% of propionic acid production (Ogier de Baulny et al, 2012).
6. NURSING MANAGEMENT OF THE PATIENT WITH METHYLMALONIC ACIDURIA

Nursing observation and attention to detail is vital. The reporting of episodes of vomiting or diarrhoea or headache and instigation of treatment may be life-saving.

<table>
<thead>
<tr>
<th>ACTION</th>
<th>RATIONALE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. GENERAL OBSERVATIONS:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>SKIN</strong></td>
<td></td>
</tr>
<tr>
<td>• Assess colour, peripheral perfusion</td>
<td></td>
</tr>
<tr>
<td>• Assess if intact / dry / broken (especially skin folds and nappy area).</td>
<td></td>
</tr>
<tr>
<td>• Ensure skin is kept clean and dry and nappy is changed frequently.</td>
<td></td>
</tr>
<tr>
<td><strong>HAIR</strong></td>
<td></td>
</tr>
<tr>
<td>• Assess if coarse / brittle / alopecia present</td>
<td></td>
</tr>
<tr>
<td>ACTION</td>
<td>RATIONALE</td>
</tr>
<tr>
<td>--------</td>
<td>-----------</td>
</tr>
<tr>
<td><strong>WEIGHT</strong>&lt;br&gt;• Measure weight</td>
<td>To assist in assessment of hydration status. To ensure medications dosage and dietary prescriptions are correct.</td>
</tr>
<tr>
<td><strong>2. NEUROLOGICAL STATUS:</strong>&lt;br&gt;Assess <em>neurological status</em> using Glasgow Coma Scale to demonstrate altered levels of consciousness, muscle weakness or seizures. If ambulant observe for ataxia and report to medical team.</td>
<td>Risk of encephalopathy secondary to hyperammonaemia.&lt;br&gt;Seizures resulting from hypoglycaemia.</td>
</tr>
<tr>
<td><strong>3. VITAL SIGNS:</strong>&lt;br&gt;TEMPERATURE&lt;br&gt;Monitor temperature 4 hourly or more frequently if indicated.</td>
<td>Pyrexia of over 38.5° Celsius may indicate underlying infection. F.B.C., L.F.T’S, blood cultures, serum amino acids, blood gas and urine for quantitative MMA. Levels should be obtained to evaluate condition.</td>
</tr>
</tbody>
</table>
Report abnormalities in vital signs to the metabolic team.

- **PULSE**
  
  Hypothermia may suggest need for more calories or may indicate overwhelming infection.
  
  Tachycardia may indicate:
  - Infection
  - Acidosis
  - Fluid overload
  - Dehydration

- **RESPIRATION**
  
  Tachypnoea may indicate:
  - Infection
  - Fluid
  - Acidosis - can have a metabolic acidosis with an increased anion gap (Ogier de Baulny et al, 2012)

4. **URINE:**
If unwell, urine should be obtained for quantitative MMA levels and / or qualitative analysis for Propionic metabolites.

Levels of MMA in the urine alter constantly and normal levels are particular to the individual. Elevated MMA may prompt reduction of natural protein intake (decided by Metabolic Consultant).
<table>
<thead>
<tr>
<th>ACTION</th>
<th>RATIONALE</th>
</tr>
</thead>
<tbody>
<tr>
<td>(5-10 mls – Universal container – must be frozen until transfer to the laboratory ) If on I.V. Dextrose infusion, test urine regularly for glucose. Inform Metabolic team if glycosuria is present. Urinalysis carried out on admission &amp; daily thereafter.</td>
<td>It may not be possible to reduce rate / concentration of glucose infusion due to calorie requirements. An insulin infusion may be prescribed (decided by Metabolic Consultant). - Ketonuria is a common finding and indicates catabolism – prompt action is required. - Elevated urine pH and metabolic acidosis in blood may indicate renal tubular acidosis with increased bicarbonate losses (tubulopathy). - Specific gravity - Indication of level of hydration. Increased specific gravity occurs in case of dehydration. Decreased specific gravity occurs in patients with renal failure or after excessive fluid intake. Present if catabolic / ketoacidosis.</td>
</tr>
</tbody>
</table>

5. **BLOOD GLUCOSE & LACTATE**
Measure 4-6 hourly when unwell and while on intravenous therapy.

Hypoglycaemia and hyperlactataemia are frequently found in patients with MMA (Ogier de Baulny et al, 2012).

Hyperglycaemia may occur as a result of high dextrose concentration / volumes required to fulfil calorie requirements.

Refer to Medical Guidelines handbook regarding prescription of insulin and consult Metabolic Consultant / Registrar on call. Insulin doses appropriate for use in patients with Insulin Dependent diabetes are not appropriate for use in Metabolic Patients.
6. **DIET:**

**NATURAL PROTEIN**
On initial presentation and during episodes of illness and crisis, protein intake will be discontinued or restricted (decision will be taken by consultant).

Initially, infants will receive their protein requirements from infant formula. Consequently, protein content of solids introduced from weaning onwards must be included in total daily protein allowance.

Protein allowance is counted in ‘exchanges’

1 gram of natural protein = 1 exchange

**SYNTHETIC PROTEIN**
(Amino Acid drink).

Necessary for normal growth and development.

Supplements natural protein. Contains all amino acids except those that cannot be metabolized.

Wide range of low protein products available to provide variety in diet, curb hunger and provide energy.
**ACTION** | **RATIONALE**
--- | ---
**LOW PROTEIN / PROTEIN FREE PRODUCTS**<br>Carbohydrate and Fat (maxijul and fat solution) or Energyvits (proprietary formula).<br><br>**EMERGENCY / UNWELL REGIME**<br>Different regimes may be prescribed according to patients’ status.<br>- Natural Protein: may be ¼, ½, ¾, or full (i.e. proportion of normal daily protein intake).<br>- Synthetic Protein may be reduced only if patient is very unwell.<br>- Prescribed calorie intake may be increased by 10 % or 20% of normal daily calorie intake (referred to as 110% or 120% calories).<br><br>Provides calories required to prevent catabolism. Do not contain amino acids.<br><br>The reduction of natural protein reduces the risk of encephalopathy.<br><br>Increasing calorie intake prevents catabolism, thus reducing the risk of encephalopathy.
**ACTION**

- Calorie intake should be recorded for the child who is unwell.

- Nasogastric feeding may be necessary if not taking oral diet. If enteral feeding is not tolerated, intravenous nutrition will be required, i.e. - I.V. Dextrose (carbohydrate) - I.V lipids (fat) - I.V. Vaminolact (natural protein)

**RATIONALE**

Calorie count ensures patient is receiving adequate calories to promote health and prevent catabolism.

To ensure adequate amounts of protein, fat and calories are achieved to meet daily requirements.

---

**7. INTAKE AND OUTPUT**

Calculate mls / kg / 24hrs

i.e. Total mls in 24hr period ÷ body weight in kgs.

- Record losses
  - Vomit & stools & Urine output

To ensure adequate fluid intake and early detection of fluid overload.

Losses may need to be replaced. Dehydration in MMA is very common as the renal clearance of Methylmalonic acid is very high and induces diuresis (Saudubray et al, 1991).
8. **MEDICATIONS**

- **Adenosylcobalamin (Vit B₁₂)**
  Administered by IM injection. Dose and frequency are titrated according to urinary MMA results.

- **Carnitine**
  Usually administered orally, but may be given intravenously.

- **Vitamins and minerals**
  Necessary for the enzyme Methylmalonyl Co-A Mutase to function effectively.
  Transports toxic acyl-CoA compounds from the cell for excretion. 100mg / kg per day is recommended to replenish free carnitine used in the excretion of toxic compounds (Yannicelli, 1988). Usually supplemented orally. Increased oral doses can cause frequent passage of loose stools, IV carnitine can be given as an alternative.
  Supplementation may be necessary due to synthetic nature of the prescribed diet.

9. **EDUCATION**

- Teaching is an on-going process.

  Involves several members of the multidisciplinary team.

  - Diet – includes preparation of feeds.
<table>
<thead>
<tr>
<th>ACTION</th>
<th>RATIONALE</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Well and Unwell Regimes</td>
<td>Volumes and calorific / protein content need to be adjusted according to condition.</td>
</tr>
<tr>
<td>• Medications (side effects, IM administration etc.).</td>
<td></td>
</tr>
<tr>
<td>• Nasogastric tube insertion and use (if required).</td>
<td>Ensures patient safety</td>
</tr>
<tr>
<td>• Signs &amp; Symptoms of illness – implications of delayed treatment or untreated illness.</td>
<td></td>
</tr>
</tbody>
</table>

10. MULTIDISCIPLINARY / FOLLOW UP CARE.

• Metabolic Clinic for dietetic, medical and nursing support.

• **Blood testing** at each OPD visit e.g. amino acids
<table>
<thead>
<tr>
<th>ACTION</th>
<th>RATIONALE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Urine</strong> samples may be requested at intervals between OPD visits. (Quantitative MMA)</td>
<td>Chronic illness may have adverse effects on the family unit and relationships within the family. Psychologist and Social Worker input are necessary to assess coping mechanisms and difficulties with diet etc.</td>
</tr>
<tr>
<td><strong>Psychology</strong></td>
<td>To ensure that appropriate entitlements and services are accessed.</td>
</tr>
<tr>
<td><strong>Social Work</strong></td>
<td>Implications for future pregnancies 25% risk of occurrence in other pregnancies to same partners.</td>
</tr>
<tr>
<td><strong>Speech &amp; Language Therapy</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Genetic counselling</strong></td>
<td></td>
</tr>
</tbody>
</table>
7. REVIEW:
This procedure shall be reviewed and updated at least every two years by the Clinical Education Facilitator, NCIMD in order to determine its effectiveness and appropriateness. It shall be assessed and amended as necessary during this period to reflect any changes in best practice, law, substantial organisational change and professional or academic change.

8. REFERENCES:
Methylmalonic Acidaemia


